Eficacia del manejo farmacológico de la dislipidemia en la prevención primaria de eventos cardiovasculares.

Abstract

Introduction: Cardiovascular disease is the main cause of morbidity and mortality a world level, it is among the leading causes of mortality in the world, closely linked to diabetes. The pharmacological control of lipids plays an important role in preventing cardiovascular events, so it is essential to recognize the patients that have the greatest benefit with this therapy. Objective: To evaluate the efficacy of lipid-lowering drugs in the primary prevention of cardiovascular events through the review of updated literature. Methodology: We searched the literature published between 2014 and 2018 in the databases Pubmed, Intramed, Medscape, Cochrane library, Elsevier, Circulation, Journal of the American College of Cardiology, American association of clinical endocrinologists, American diabetes association, European society of cardiology on the treatment of dyslipidemia. Primary prevention articles were included, as well as relevant clinical practice guidelines. The main lipid-lowering drugs were evaluated separately for an individual analysis. Conclusions: Dyslipidemia increases the risk of premature heart disease and residual risk. Statins, ezetimibe, PCSK9 inhibitors significantly reduce the risk of cardiovascular disease and mortality; they are safe in patients ≥ 75 years with diabetes and moderate CRI. The fibrates. Omega-3 supplements, drugs for low HDL-C do not demonstrate cardiovascular benefit. However, omega-3 can have benefits in high doses in selected patients.